idw – Informationsdienst Wissenschaft
Nachrichten, Termine, Experten
Nachrichten, Termine, Experten
Greifswald, 24 June 2025 – On the occasion of the 20th anniversary of its first successful spin-off, the Leibniz Institute for Plasma Science and Technology (INP) looks back on two decades of intensive transfer work. Since 2003, the institute has pursued a strategically oriented transfer policy that translates scientific findings into marketable applications. Six spin-offs have been created as part of this strategy – proof of the successful transfer of research results into practice.
‘As a publicly funded institute, it is our mission to create direct benefits for society through our research. Successful transfer is a central component of this,’ says Prof. Dr. Klaus-Dieter Weltmann, Chairman of the Executive Board and Scientific Director of INP. "Our motto “From idea to prototype” is not just a slogan, but a way of life. We accompany technologies from the basic idea to market maturity – together with partners from research, industry and clinics."
The INP's transfer strategy is closely linked to the goals of the Leibniz Association. The association sees itself as a bridge between science, society and industry and actively supports the commercial exploitation of research results.
Six successful spin-offs – regional roots, international impact
Since neoplas GmbH was founded in 2005, the INP has spun off a total of six companies together with partners. neoplas GmbH acts as a technology transfer centre and forms the bridge between scientific development and industrial application. One year later, neoplas control GmbH followed, a company specialising in the development of measurement and control technology for plasma processes.
In the medical field, neoplas med GmbH was founded in 2009. Its best-known product, kINPen® MED, is approved for the treatment of chronic wounds. In 2015, ColdPlasmaTech GmbH joined the ranks of companies active in the field of plasma medicine, focusing on applications for large-area wounds. Both companies have attracted international investors.
Nebula Biocides GmbH, founded in 2019, is developing an innovative disinfection process that does not require alcohol or chemical residues. The most recent spin-off is elementarhy GmbH, founded in 2024, which is developing plasma-based processes for key components of green hydrogen production.
‘Revenue from patents, licences, industrial projects and collaborations enables us to support spin-offs as they enter the market, thereby creating jobs in the region,’ adds Weltmann.
Technology transfer at the INP is not only a regional economic factor, but also contributes to Germany's innovative strength. Close cooperation with industry, involvement in clinical studies and international partnerships result in products that are used worldwide – whether in medical technology, environmental technology or industrial production.
The Leibniz Institute for Plasma Science and Technology (INP) in Greifswald: For 20 years, the insti ...
Copyright: INP
Criteria of this press release:
Business and commerce, Journalists
Energy, Medicine, Physics / astronomy
transregional, national
Transfer of Science or Research
English
The Leibniz Institute for Plasma Science and Technology (INP) in Greifswald: For 20 years, the insti ...
Copyright: INP
You can combine search terms with and, or and/or not, e.g. Philo not logy.
You can use brackets to separate combinations from each other, e.g. (Philo not logy) or (Psycho and logy).
Coherent groups of words will be located as complete phrases if you put them into quotation marks, e.g. “Federal Republic of Germany”.
You can also use the advanced search without entering search terms. It will then follow the criteria you have selected (e.g. country or subject area).
If you have not selected any criteria in a given category, the entire category will be searched (e.g. all subject areas or all countries).
